AgingResearch.NewsJoin free
medRxiv

Buckwheat powder did not beat placebo on main cognition measure

The main self-rated cognitive-function score changed at similar rates with buckwheat and placebo, with a difference of 0.03 during the 12-week trial.

Paper by K. P. White, J. L. Tartar, M. Roel, +5 more authorsS. J. Hewlings · Radicle Science, Inc.
Brain sections with similar folds sit above small groups of people, with buckwheat sprouts and scattered powder beside the larger section.

Our read

Interventions
Studied:
Preprint: randomized trial in 662 US adults with self-reported cognitive difficulties, against matched placebo (Double-blind, placebo-controlled, registered NCT07245784)
What changed:
Self-rated cognitive function did not improve more with buckwheat powder than with placebo
The catch:
Only 662 of 848 randomized participants were analyzed
Why it’s aging research:
It measures an outcome that worsens with age.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

US adults with self-reported cognitive difficulties received 18 grams daily of Himalayan Tartary buckwheat sprout powder or matched placebo for 12 weeks. The randomized, double-blind trial assigned 848 participants; 662 were analyzed. The main questionnaire measure of cognitive function did not improve more with buckwheat than placebo.

A separate self-rated abilities score improved faster with buckwheat, but the difference did not hold after adjustment for multiple comparisons. Among 296 participants with final-week data, meaningful improvement on that score occurred in 68.7% receiving buckwheat and 52.5% receiving placebo. Exploratory computerized tests in 512 participants found faster reaction times without reduced accuracy. Fatigue, sleep-related impairment and depressive symptoms did not differ between groups. Side-effect rates were similar.

Why it matters

Everyday cognitive difficulties are common in midlife and later life. The trial addressed whether a food-based approach could support thinking during these stages of life.

Caveats

The analysis included only 662 of 848 randomized participants, and the final-week comparison covered 296. The preprint has not been peer-reviewed; its results may not apply to people without self-reported cognitive difficulties.

Comments

Be the first to comment.

Related